Abrocitinib
- Generic Name
- Abrocitinib
- Brand Names
- Cibinqo
- Drug Type
- Small Molecule
- Chemical Formula
- C14H21N5O2S
- CAS Number
- 1622902-68-4
- Unique Ingredient Identifier
- 73SM5SF3OR
- Background
Abrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Janus kinases are intracellular enzymes involved in transduction pathways that regulate hematopoiesis and immune cell function. The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of aut...
- Indication
Abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. In the US, it is indicated to treat refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inad...
- Associated Conditions
- Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate, refractory Atopic dermatitis, Refractory, severe Atopic Dermatitis
- Associated Therapies
- -
Study to Investigate the Efficacy of Abrocitinib in Adult Participants with Severe Fatigue from Post COVID Condition/Long COVID
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT06597396
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Target Recruit Count
- 150
- Registration Number
- NCT06573593
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, China
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Peng Zhang
- Target Recruit Count
- 30
- Registration Number
- NCT06119490
- Locations
- 🇨🇳
Department of Dermatology, the First Affiliated Hospital of Fujian Medical University., Fuzhou, Fujian, China
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT05721937
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
- Conditions
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 183
- Registration Number
- NCT05689151
- Locations
- 🇫🇷
CHU Amiens-Picardie - Site Nord, Amiens, Somme, France
🇫🇷Chu Estaing, Clermont Ferrand Cedex 1, France
🇫🇷CHU Besancon - Hopital Jean Minjoz, Besancon, France
Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Innovaderm Research Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05602207
- Locations
- 🇺🇸
Inno-6050 Site 19, Saint Petersburg, Florida, United States
🇨🇦Inno-6050 Site 14, Québec, Quebec, Canada
🇨🇦Inno-6050 Site 20, Québec, Quebec, Canada
Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)
- Conditions
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05466578
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
- Conditions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3000
- Registration Number
- NCT05391061
- Locations
- 🇰🇷
Pfizer Tower, Seoul, Korea, Republic of
JAK Inhibition in Food Allergy
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 40
- Registration Number
- NCT05069831
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT05067439
- Locations
- 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.